In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can MicroPort Master Orthopedics?

Executive Summary

China’s MicroPort Scientific paid $290 million in cash for Wright Medical’s hip and knee business, which has a pipeline of products – including FDA approved implants – ready for sale in China’s growing orthopedics market. The acquisition pits MicroPort against multinationals that previously held an edge selling implants to Chinese patients and doctors who seem to favor devices that carry approval from the US FDA.

Advertisement

Related Content

The Year In Review: Device Trends To Watch In 2014
ArthroCare Bid Signals Ortho Consolidation
ArthroCare Bid Signals Ortho Consolidation
Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
MicroPort’s Wright Bid Creates New Ortho Player
At AAOS Knee Implant Makers Pitch Better Fit, Precision
Kanghui: A New Strategic Opens The Door To Orthopedics In China
Is Wright Medical Back on Track?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel